List view / Grid view
Biogen Idec announced that Richard (Rick) A. Rudick, M.D., has…
12 May 2014 | By Biogen Idec
Biogen Idec announced that Richard (Rick) A. Rudick, M.D., has joined the company as vice president, Development Sciences, Value-Based Medicine...
Biogen Idec announced that a post hoc analysis of data…
1 May 2014 | By Biogen Idec
Biogen Idec announced that a post hoc analysis of data from the AFFIRM study shows TYSABRI® (natalizumab) significantly increased the proportion of relapsing-remitting multiple sclerosis patients with confirmed improvement in walking speed...
Additional real-world data show tolerability profile consistent with pivotal studies...
30 April 2014 | By Biogen Idec
Additional real-world data show tolerability profile consistent with pivotal studies...
Quintiles and Biogen Idec have entered into a five-year strategic…
24 April 2014 | By Biogen Idec
Quintiles and Biogen Idec have entered into a five-year strategic clinical development agreement...
Biogen Idec will present more than 60 company-sponsored platform and…
14 April 2014 | By Biogen Idec
Biogen Idec will present more than 60 company-sponsored platform and poster presentations on data supporting its marketed and investigational therapies for neurological diseases at the 66th American Academy of Neurology Annual Meeting...
“These analyses build upon a growing body of evidence that…
3 October 2013 | By Biogen Idec
“These analyses build upon a growing body of evidence that demonstrates greater clinical benefits for people with MS when TYSABRI is initiated earlier in the course of the disease..."
Biogen Idec and Elan have submitted applications to the U.S.…
16 January 2013 | By Biogen Idec
Biogen Idec and Elan have submitted applications to the U.S. FDA...
New data from studies evaluating oral BG-12...
12 October 2012 | By Biogen Idec
New data from studies evaluating oral BG-12...
Results from 11 company-sponsored TYSABRI presentations...
11 October 2012 | By Biogen Idec
Results from 11 company-sponsored TYSABRI presentations...
Extensive data from MS franchise...
10 October 2012 | By Biogen Idec
Extensive data from MS franchise...
Biogen Idec and Abbott announced additional results from the SELECT…
22 October 2011 | By Biogen Idec
Biogen Idec and Abbott announced additional results from the SELECT Phase 2b trial...
